CIPLA TO MANUFACTURE ANTI-INFECTIVE FOR AKORN

Indian-based pharmaceutical company Cipla has entered into an agreement to manufacture and supply an oral anti-infective drug product to US-based Akorn. Under the terms of the ten-year agreement, Cipla will be responsible for the manufacturing and supply of the drug using Akorn's formulation, and Akorn will be responsible for the abbreviated new drug application (ANDA) regulatory submission and clinical development, and for the purchase of specialized manufacturing equipment.
Pharmaceutical Business Review